Literature DB >> 16175221

Lamotrigine-induced rash: Can we stop worrying?

Andres M Kanner.   

Abstract

Entities:  

Year:  2005        PMID: 16175221      PMCID: PMC1201641          DOI: 10.1111/j.1535-7511.2005.00060.x

Source DB:  PubMed          Journal:  Epilepsy Curr        ISSN: 1535-7511            Impact factor:   7.500


× No keyword cloud information.
  5 in total

Review 1.  Safety review of adult clinical trial experience with lamotrigine.

Authors:  J Messenheimer; E L Mullens; L Giorgi; F Young
Journal:  Drug Saf       Date:  1998-04       Impact factor: 5.606

2.  Adding valproate to lamotrigine: a study of their pharmacokinetic interaction.

Authors:  A M Kanner; M Frey
Journal:  Neurology       Date:  2000-08-22       Impact factor: 9.910

3.  Lamotrigine-induced rash--worth a rechallenge.

Authors:  S P-Codrea Tigaran; P Sidenius; M Dam
Journal:  Acta Neurol Scand       Date:  2005-03       Impact factor: 3.209

4.  Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics.

Authors:  Maja Mockenhaupt; John Messenheimer; Pat Tennis; Juergen Schlingmann
Journal:  Neurology       Date:  2005-04-12       Impact factor: 9.910

5.  Sodium valproate acutely inhibits lamotrigine metabolism.

Authors:  A W Yuen; G Land; B C Weatherley; A W Peck
Journal:  Br J Clin Pharmacol       Date:  1992-05       Impact factor: 4.335

  5 in total
  1 in total

1.  Pharmacotherapeutics of epilepsy: use of lamotrigine and expectations for lamotrigine extended release.

Authors:  Mary Ann Werz
Journal:  Ther Clin Risk Manag       Date:  2008-10       Impact factor: 2.423

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.